AKERO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.07 USD | +3.79% |
|
+0.24% | -9.76% |
Presenter SpeechMatthew Harrison (Analysts)So great. Thanks for joining us again this afternoo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Calendar
2024-06-07
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
21.07
USD
Average target price
45.12
USD
Spread / Average Target
+114.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.76% | 1.46B | |
| +7.52% | 113B | |
| +11.38% | 106B | |
| +0.79% | 22.27B | |
| -12.64% | 22.22B | |
| -4.59% | 19.43B | |
| -37.85% | 17.87B | |
| -8.58% | 17.24B | |
| +7.77% | 14.29B | |
| +37.41% | 12.52B |
- Stock Market
- Equities
- AKRO Stock
- News Akero Therapeutics, Inc.
- Transcript : Akero Therapeutics, Inc. Presents at Morgan Stanley 18th Annual Global Healthcare Conference, Sep-14-2020 03
